Axcelis Technologies (ACLS) Tops Q2 Earnings and Revenue Estimates — Positive
ACLS Zacks Investment Research — August 05, 2025Axcelis Technologies (ACLS) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $1.55 per share a year ago.
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates — Neutral
ACIU Zacks Investment Research — August 05, 2025AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.25 per share a year ago.
AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates — Positive
AXGN Zacks Investment Research — August 05, 2025AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.05 per share a year ago.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates — Negative
BEAM Zacks Investment Research — August 05, 2025Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.11 per share a year ago.
Cushman & Wakefield (CWK) Surpasses Q2 Earnings and Revenue Estimates — Positive
CWK Zacks Investment Research — August 05, 2025Cushman & Wakefield (CWK) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.2 per share a year ago.
Fidelity National Information Services (FIS) Matches Q2 Earnings Estimates — Positive
FIS Zacks Investment Research — August 05, 2025Fidelity National Information Services (FIS) came out with quarterly earnings of $1.36 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.36 per share a year ago.
J&J Snack Foods (JJSF) Beats Q3 Earnings and Revenue Estimates — Positive
JJSF Zacks Investment Research — August 05, 2025J&J Snack Foods (JJSF) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.74 per share. This compares to earnings of $1.98 per share a year ago.
AdaptHealth Corp. (AHCO) Lags Q2 Earnings and Revenue Estimates — Negative
AHCO Zacks Investment Research — August 05, 2025AdaptHealth Corp. (AHCO) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.21 per share a year ago.
LCI (LCII) Q2 Earnings and Revenues Top Estimates — Positive
LCII Zacks Investment Research — August 05, 2025LCI (LCII) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.4 per share a year ago.
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates — Negative
MDGL Zacks Investment Research — August 05, 2025Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a loss of $7.1 per share a year ago.
Sealed Air (SEE) Q2 Earnings and Revenues Beat Estimates — Positive
SEE Zacks Investment Research — August 05, 2025Sealed Air (SEE) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.83 per share a year ago.
Knife River (KNF) Misses Q2 Earnings and Revenue Estimates — Negative
KNF Zacks Investment Research — August 05, 2025Knife River (KNF) came out with quarterly earnings of $0.89 per share, missing the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.37 per share a year ago.
UL Solutions Inc. (ULS) Q2 Earnings and Revenues Surpass Estimates — Positive
ULS Zacks Investment Research — August 05, 2025UL Solutions Inc. (ULS) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.44 per share a year ago.
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates — Neutral
TNGX Zacks Investment Research — August 05, 2025Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.24 per share a year ago.
President Trump: Going to raise India tariffs very substantially since they're buying Russian oil — Negative
BNO DBO GUSH IEO OIH OIL PXJ UCO USO XOP CNBC Television — August 05, 2025President Donald Trump joins 'Squawk Box' via phone to discuss the trade negotiations around the world, the oil policy and much more.
Parsons and Globalstar Pave Way for Commercial Satellite Solutions after Completing Successful Proof of Concept — Neutral
GSAT PSN Business Wire — August 05, 2025COVINGTON, La.--(BUSINESS WIRE)--Globalstar (NASDAQ: GSAT), a next-generation telecommunications infrastructure and technology provider, and Parsons Corporation, a global leader in national security and critical infrastructure solutions, (NYSE: PSN) today announced a significant step toward commercial availability of a joint solution that integrates Globalstar's Low Earth Orbit (LEO) satellite capabilities with Parsons' advanced software-defined communication technologies. This collaborative ef.
Align Technology Is A Buy: Secular Headwinds Temporary, Market Dominance Enduring — Positive
ALGN Seeking Alpha — August 05, 2025Align Technology, Inc. holds dominant market share in clear aligners and related hardware/software, with strong international growth potential despite recent U.S. demand softness. Current revenue and margin pressures are largely macro-driven and cyclical; management is proactively cutting costs and optimizing operations to maintain profitability. The company boasts a robust balance sheet, healthy cash flow, and is trading at historically low valuation multiples, offering an attractive risk-reward profile.
Olo (OLO) Q2 Revenue Jumps 22%
Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 — Neutral
LGVN GlobeNewsWire — August 05, 2025MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m.
2 High-Yield Preferreds For Non-Cyclical Retirement Income — Negative
BEP Seeking Alpha — August 05, 2025Valuations are clearly not in synch with the economic reality. While it's dangerous to bet against the market, taking a more cautious approach while preserving high yields is not. I lay out the overall case for preferred shares and discuss two attractive preferred shares offering high and durable income potential.